Pio R - Search Results

1

SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays.

Anton MA, Gorostiaga D, Guruceaga E, Segura V, Carmona-Saez P, Pascual-Montano A, Pio R, Montuenga LM, Rubio A. Anton MA, et al. Among authors: pio r. Genome Biol. 2008;9(2):R46. doi: 10.1186/gb-2008-9-2-r46. Epub 2008 Feb 29. Genome Biol. 2008. PMID: 18312629 Free PMC article.

2

Fasting and fasting-mimicking conditions in the cancer immunotherapy era.

Pio R, Senent Y, Tavira B, Ajona D. Pio R, et al. J Physiol Biochem. 2024 Apr 8. doi: 10.1007/s13105-024-01020-3. Online ahead of print. J Physiol Biochem. 2024. PMID: 38587595 Review.

3

Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.

Pino I, Pío R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, García-Foncillas J, Montuenga LM. Pino I, et al. Among authors: pio r. Lung Cancer. 2003 Aug;41(2):131-43. doi: 10.1016/s0169-5002(03)00193-4. Lung Cancer. 2003. PMID: 12871776 Free article.

4

Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene.

Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Carretero J, et al. Among authors: pio r. Oncogene. 2004 May 13;23(22):4037-40. doi: 10.1038/sj.onc.1207502. Oncogene. 2004. PMID: 15021901 Free article.

5

Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.

Pio R, Zudaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, Calasanz MJ, Montuenga LM. Pio R, et al. Cancer Res. 2004 Jun 15;64(12):4171-9. doi: 10.1158/0008-5472.CAN-03-2982. Cancer Res. 2004. PMID: 15205328 Free article.

6

Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.

Ajona D, Castaño Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, Cuttitta F, Montuenga LM, Pio R. Ajona D, et al. Among authors: pio r. Cancer Res. 2004 Sep 1;64(17):6310-8. doi: 10.1158/0008-5472.CAN-03-2328. Cancer Res. 2004. PMID: 15342420

7

Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing.

Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, Port JD, Montuenga LM, Malkinson AM. Zerbe LK, et al. Among authors: pio r. Mol Carcinog. 2004 Dec;41(4):187-96. doi: 10.1002/mc.20053. Mol Carcinog. 2004. PMID: 15390079

8

Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.

Pajares MJ, Zudaire I, Lozano MD, Agorreta J, Bastarrika G, Torre W, Remírez A, Pio R, Zulueta JJ, Montuenga LM. Pajares MJ, et al. Among authors: pio r. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):373-80. doi: 10.1158/1055-9965.EPI-05-0320. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492931

9

Alternative splicing: an emerging topic in molecular and clinical oncology.

Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Pajares MJ, et al. Among authors: pio r. Lancet Oncol. 2007 Apr;8(4):349-57. doi: 10.1016/S1470-2045(07)70104-3. Lancet Oncol. 2007. PMID: 17395108 Review.

10

Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.

Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Ajona D, et al. Among authors: pio r. J Immunol. 2007 May 1;178(9):5991-8. doi: 10.4049/jimmunol.178.9.5991. J Immunol. 2007. PMID: 17442984

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters